Wells Fargo & Company Rapt Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
A detailed history of Wells Fargo & Company transactions in Rapt Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 19,291 shares of RAPT stock, worth $62,888. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19,291
Previous 12,490
54.45%
Holding current value
$62,888
Previous $310,000
44.19%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding RAPT
# of Institutions
148Shares Held
29.1MCall Options Held
709KPut Options Held
1.06M-
Column Group LLC San Francisco, CA2.68MShares$8.74 Million15.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.49MShares$8.13 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.47MShares$8.06 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.03MShares$6.61 Million0.0% of portfolio
-
Morgan Stanley New York, NY1.91MShares$6.21 Million0.0% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $96.7M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...